AI in Bio Weekly Review: Nkarta & CRISPR's Zero-CRS Autoimmune Feat, Delix's $100M Neuroplastogen Round, Lilly's Sleep Apnea Hit, and bioRxiv Dark Proteome AI — November 3–9, 2026
The seven-day window spanning November 3–9, 2026 delivered watershed clinical validation for allogeneic cell therapy in rheumatology, computational neuroplasticity capital formation, and frontier proteomic foundation models: Nkarta and CRISPR Therapeutics unveiled transformative Phase 1 data in myositis and scleroderma with zero CRS or neurotoxicity; Delix secured $100M from J&J and DDF for non-hallucinatory psychoplastogen DLX-001; Eli Lilly unblinded Phase 3 ATTAIN-OSA sleep apnea efficacy for oral GLP-1 Foundayo in JAMA; bioRxiv introduced π-SPECFormer (291M spectra) and RPI-Zero; Windward Bio set a $204M Nasdaq IPO backed by Sanofi; Edesa and Kyorin inked a $140M ARDS pact; and AHA late-breakers reset cardiovascular targets.
The seven-day window spanning November 3–9, 2026 crystallized a historic paradigm shift across computational biology, cell therapy engineering, and precision pharmacology. For the past three years, the biopharma landscape has wrestled with four central structural dilemmas:
- Whether cell therapy for severe autoimmune disease could ever move beyond autologous logistics, crippling manufacturing turnaround times, and life-threatening cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS);
- Whether the profound neuroplastic benefits of psychedelics could be rationally dissociated from hallucinogenic signaling through structural chemistry to enable at-home psychiatric therapies;
- Whether oral, non-peptide GLP-1 receptor agonists could match injectable biologics in structural, multi-organ pathology beyond glycemic control; and
- Whether biological foundation models could transcend single-protein 3D coordinate folding into unannotated mass spectrometry data and zero-shot RNA interactome inference.
Over the past week, decisive clinical presentations at ACR Convergence 2026 in Orlando, late-breaking cardiovascular readouts at the AHA Scientific Sessions 2026 in Chicago, oversubscribed private financing rounds, and landmark bioRxiv preprints answered every single one of these questions with rigorous empirical data.
At ACR Convergence 2026, Nkarta, Inc. (NASDAQ: NKTX) and CRISPR Therapeutics (NASDAQ: CRSP) delivered the definitive clinical breakthrough for off-the-shelf cellular medicine. Reporting on 40 patients across five refractory autoimmune indications in its Phase 1/2 Ntrust basket program, Nkarta demonstrated that its allogeneic CD19 CAR-NK cell candidate NKX019 achieved an 83% clinical response rate in myositis and an 86% rCRISS-25 response rate in systemic sclerosis (SSc)—paired with a median 15-point drop in modified Rodnan skin score (mRSS)—with zero cases of CRS, zero ICANS, and zero graft-versus-host disease (GvHD). Concurrently, CRISPR Therapeutics reported that its multiplex CRISPR/Cas9-edited allogeneic CD19 CAR-T zugocabtagene geleucel (zugo-cel / CTX112) induced rapid clinical remissions with zero Grade >2 CRS and zero ICANS. Coming days after autologous CAR-T safety deaths forced competitor pipeline shutdowns, these dual presentations establish allogeneic immune resetting as the future standard of care for autoimmune diseases.
In neuropharmacology and computational drug design, Delix Therapeutics closed an oversubscribed $100 million Series C financing co-led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund (DDF). By reverse-engineering 5-MeO-DMT through structural modeling to decouple cortical synaptogenesis (TrkB/mTOR signaling) from 5-HT2A hallucinogenesis, Delix is advancing its lead psychoplastogen zalsupindole (DLX-001) into a pivotal Phase 2b trial for recurrent Major Depressive Disorder (MDD), unlocking a scalable oral therapy taken at home without the mandatory two-hour in-clinic monitoring bottleneck of esketamine or psilocybin.
Simultaneously, at the AHA Scientific Sessions in Chicago, Eli Lilly and Company (NYSE: LLY) presented Phase 3 ATTAIN-OSA data simultaneously published in the Journal of the American Medical Association (JAMA), demonstrating that its oral once-daily GLP-1 receptor agonist Foundayo (orforglipron / LY3502970) reduced the apnea-hypopnea index (AHI) by 43.8% (21.1 fewer breathing events per hour) and slashed hypoxic burden by 55.9% in adults with moderate-to-severe obstructive sleep apnea and obesity not using CPAP machines. Lilly confirmed it will submit an FDA supplemental New Drug Application (sNDA) by year-end 2026.
In the AI foundation model space, bioRxiv preprints expanded computational biology into previously dark biological layers. Researchers unveiled $\pi$-SPECFormer, a mass spectrometry foundation model pretrained across 291 million spectra, which decoded the “dark proteome” of lung adenocarcinoma to uncover non-canonical somatic mutated peptides. Alongside this, the Cicek Lab introduced RPI-Zero, the first sequence-only foundation model to achieve zero-shot RNA-protein interaction prediction across unprofiled molecules using 16 shared motif prototypes evaluated on 2.1 million strict non-leaking pairs.
Finally, in public markets and global business development, Windward Bio Group AG filed terms for a up to $204 million Nasdaq IPO (WWB) backed by a $50 million concurrent private placement commitment from Sanofi, while Edesa Biotech (NASDAQ: EDSA) executed an exclusive $140 million licensing pact with KYORIN Pharmaceutical for Japanese rights to its TLR4 antibody paridiprubart in Acute Respiratory Distress Syndrome (ARDS). Meanwhile, full late-breaking Phase 3 data for Novartis’ pelacarsen (Lp(a)HORIZON) in the New England Journal of Medicine (NEJM) confirmed a lack of MACE benefit despite a 78% Lp(a) drop, and Novo Nordisk’s ziltivekimab (ZEUS) missed its composite cardiovascular endpoint, enforcing a strict mechanistic reality check across cardiovascular R&D.
The Headlines at a Glance
| Sector / Category | Organization / Entity | Asset / Program / Topic | Milestone / Core Breakthrough | Strategic & Biophysical Significance | Source / Verification |
|---|---|---|---|---|---|
| Allogeneic Cell Therapy | Nkarta, Inc. (NASDAQ: NKTX) & CRISPR Therapeutics (NASDAQ: CRSP) | NKX019 (CAR-NK) & Zugo-cel (CTX112) | Unblinded Phase 1/2 autoimmune data at ACR 2026: 83–86% response rates in myositis & scleroderma with Zero CRS & Zero ICANS | Validates off-the-shelf allogeneic cell therapy as safe, scalable immune reset, overcoming autologous toxicity and cost | NCT06557265 / NCT05643742 / SEC CIK 0001787400 |
| Computational Neuroplasticity | Delix Therapeutics | Zalsupindole (DLX-001) | Closed $100M Series C co-led by JJDC & DDF to initiate Phase 2b trial in Major Depressive Disorder | Decouples structural cortical synaptogenesis from 5-HT2A hallucinogenesis, enabling take-home oral dosing without clinic monitoring | Company Disclosure |
| Oral Incretin Therapeutics | Eli Lilly and Company (NYSE: LLY) | Foundayo (Orforglipron / LY3502970) | Phase 3 ATTAIN-OSA published in JAMA & presented at AHA: 43.8% AHI drop and 55.9% hypoxic burden reduction; FDA filing by end-2026 | Expands oral non-peptide GLP-1 into structural respiratory pathology, providing an oral alternative to CPAP and injectables | NCT06649045 / SEC CIK 0000059478 |
| Biological Foundation Models | bioRxiv / Ling et al. & Eren et al. | $\pi$-SPECFormer & RPI-Zero | Published mass spectrometry foundation model (291M spectra) and zero-shot RNA-protein interaction model | Extends AI in bio from 3D coordinate prediction into unannotated dark proteome mass spectra and zero-shot RNA interactomes | bioRxiv: 10.64898/2026.11.06.764812 / bioRxiv: 10.64898/2026.11.04.764286 |
| Capital Formation & Licensing | Windward Bio (WWB) & Edesa Biotech (EDSA) | WWB Pipeline & Paridiprubart (EB05) | Windward sets $204M Nasdaq IPO with $50M Sanofi commitment; Edesa licenses Japan rights to Kyorin for $140M | Demonstrates pharma appetite for de-risking balance sheets via targeted private placements and regional licensing pacts | SEC CIK 0002145089 / SEC CIK 0001540159 |
| Cardiovascular Late-Breakers | Novartis (NVS), Novo Nordisk (NVO), Boehringer / Zealand | Pelacarsen, Ziltivekimab, Survodutide | Full HORIZON data in NEJM shows pelacarsen failed MACE despite 78% Lp(a) drop; ZEUS missed; Survodutide cleared CVOT | Proves biomarker lowering (Lp(a), IL-6) does not guarantee clinical event reduction; cements survodutide CV safety | NCT04023552 / NCT05021835 / NCT06077864 |
| Oral Immunology | Johnson & Johnson (JNJ) | Icotrokinra (JNJ-2113) | Unblinded Phase 3 ICONIC-PsA 1 at ACR: 58% ACR20 vs. 41% placebo in psoriatic arthritis | First-in-class targeted oral peptide inhibitor of IL-23 receptor matches injectable biologic efficacy in late-stage rheumatology | Company Pipeline Filings |
| Public Markets Dispersion | U.S. Biotech Equities (ABEO, SKYE, TVRD) | Corporate Filings vs. Thin-Float Tape | Monday Nov 9 tape: 3.9-to-1 breadth rally lifted low-float names while filings punished Abeona (-39%) and Skye (-30%) | Highlights severe divergence between discount-rate equity beta and capital-dilution document repricing | SEC CIK 0000318306 / SEC CIK 0001516551 |
1. The Allogeneic Immune-Reset Watershed: Nkarta (NKX019) and CRISPR Therapeutics (Zugo-Cel) Report Remissions with Zero-CRS at ACR Convergence 2026
The application of chimeric antigen receptor (CAR) cell therapy to severe rheumatologic and autoimmune diseases has represented one of the most promising yet operationally fragile frontiers in medicine. While autologous CD19-directed CAR-T therapies have demonstrated curative potential by depleting autoreactive B-cell clones in refractory systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), the modality has faced three severe commercialization barriers:
- Exorbitant Cost and Logistics: Autologous manufacturing requires vein-to-vein timelines of 3 to 6 weeks and costs upwards of $350,000 to $500,000 per patient, precluding widespread access in non-oncology settings.
- Myeloablative Lymphodepletion: High-dose fludarabine and cyclophosphamide preconditioning induces prolonged cytopenias, exposing vulnerable autoimmune patients to life-threatening opportunistic infections.
- Severe Inflammatory Toxicities: Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)—driven by uncontrolled in vivo CAR-T clonal expansion—frequently necessitate intensive care unit (ICU) admission and tocilizumab/corticosteroid intervention. The urgency of this safety challenge was underscored last week when patient deaths in an autoimmune cell therapy trial triggered immediate pipeline terminations across the sector.
Between November 6 and 9, 2026, at the American College of Rheumatology (ACR) Convergence 2026 annual meeting in Orlando, Florida, Nkarta, Inc. (NASDAQ: NKTX) and CRISPR Therapeutics (NASDAQ: CRSP) presented Phase 1/2 clinical data that decisively dismantled these barriers.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ THE ALLOGENEIC IMMUNE RESET IN SEVERE AUTOIMMUNE DISEASE │
├────────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Nkarta NKX019 (Allogeneic CAR-NK) │ CRISPR Therapeutics Zugo-Cel (Gene-Edited CAR-T) │
│ Phase 1/2 Ntrust Basket (40 Patients)│ Phase 1/2 Multicenter Program (21 Patients) │
├────────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ • Modality: Healthy donor CD19 CAR-NK │ • Modality: Multiplex CRISPR/Cas9-edited CAR-T │
│ • Edits: Membrane-bound IL-15 + CD19 │ • Edits: TRAC-/B2M-/TGFBR2-/Regnase-1- knockouts │
│ • Myositis (TIS Response): 83% (5 of 6)│ • Myositis (TIS Response): 100% (9 of 9 evaluable) │
│ • Systemic Sclerosis: 86% rCRISS-25 │ • Systemic Sclerosis: 83% (5 of 6) rCRISS-25 at Mo 3 │
│ • Skin Score: Median -15 pts on mRSS │ • Skin Score: Rapid mRSS reduction (36 down to 25.5) │
│ • CRS Incidence: ZERO Cases (0.0%) │ • CRS Incidence: Low Grade (No Grade >2 Events) │
│ • ICANS / Neurotoxicity: ZERO Cases │ • ICANS / Neurotoxicity: ZERO Cases (0.0%) │
│ • GvHD Incidence: ZERO Cases (0.0%) │ • GvHD Incidence: ZERO Cases (0.0%) │
└────────────────────────────────────────┴────────────────────────────────────────────────────────┘
Nkarta’s NKX019: Off-the-Shelf CAR-NK Delivers Clinical Remissions
Nkarta presented initial clinical data from its Ntrust clinical program, comprising the Ntrust-1 trial in lupus nephritis and primary membranous nephropathy (NCT06557265) and the Ntrust-2 trial in systemic sclerosis, idiopathic inflammatory myopathy (myositis), and vasculitis (NCT05020678). Across 40 patients treated across all dose levels, NKX019 demonstrated unprecedented clinical activity without a single instance of severe immune-mediated toxicity:
- Idiopathic Inflammatory Myopathy (IIM / Myositis):
- At the 4-billion-cell dose level, 83% of patients (5 of 6) with at least three months of follow-up achieved moderate or major clinical responses, as measured by the validated International Myositis Assessment and Clinical Studies (IMACS) Total Improvement Score (TIS).
- Patients experienced restoration of muscle strength, normalization of serum creatine kinase (CK) levels, and marked improvement in functional mobility.
- Systemic Sclerosis (SSc / Scleroderma):
- In patients with refractory diffuse cutaneous SSc, 86% (6 of 7) reached a revised Composite Response Index in Systemic Sclerosis (rCRISS)-25 response or greater by Day 90.
- 71% of patients (5 of 7) achieved a robust rCRISS-50 response.
- Objective reversal of skin fibrosis was observed, demonstrated by a median 15-point reduction in the modified Rodnan skin score (mRSS) at Day 90, with 71% of patients achieving at least a 50% relative reduction from baseline.
- Flawless Safety Profile Across 40 Patients:
- In 40 patients treated across five autoimmune indications, there was zero CRS, zero ICANS, zero Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS), and zero GvHD.
- Infusion-related reactions occurred in only 12.5% of patients (all Grade 1), and there were no treatment discontinuations due to adverse events and no patient deaths.
- Nkarta disclosed that based on this clean tolerability, it is compressing its outpatient dosing schedule (Days 0, 2, and 4), evaluating a higher 6-billion-cell dose tier, and meeting with the FDA in early 2027 to finalize registrational trial pathways for myositis and systemic sclerosis.
CRISPR Therapeutics’ Zugo-Cel: Multiplex Gene-Editing Conquers Allogeneic Hurdles
Complementing Nkarta’s CAR-NK data, CRISPR Therapeutics presented updated Phase 1 results in an ACR Plenary session for zugocabtagene geleucel (zugo-cel / CTX112) (NCT05643742), its investigational allogeneic CRISPR/Cas9-edited CD19 CAR-T:
- Multiplex Editing Architecture: Zugo-cel incorporates precision CRISPR edits designed to overcome host-versus-graft rejection and enhance in vivo cellular persistence. Knockouts of the T-cell receptor alpha constant (TRAC) eliminate GvHD risk; knockout of $\beta_2$-microglobulin (B2M) blunts host CD8+ T-cell rejection; and disruptive edits in TGFBR2 and ZC3H12A (Regnase-1) prevent exhaustion in hostile, TGF-$\beta$-rich inflammatory tissue microenvironments.
- Registrational-Grade Autoimmune Readouts:
- In refractory systemic sclerosis, 83% (5 of 6) of patients receiving standard lymphodepletion achieved an rCRISS-25 clinical response by Month 3, driving a median mRSS drop from 36 down to 25.5 at just 2 months.
- In idiopathic inflammatory myopathy, 100% of evaluable patients (9 of 9) achieved moderate or major TIS responses.
- Across the entire autoimmune cohort (21 patients dosed), there were no CRS events above Grade 2, and zero cases of ICANS, IEC-HS, or GvHD.
Translational & Commercial Impact
The combined data from Nkarta and CRISPR Therapeutics redefine the competitive dynamics of immunology. By establishing that allogeneic, off-the-shelf cells can completely reset the autoreactive B-cell compartment without cytokine release or neurotoxicity, these platforms eliminate the requirement for intensive inpatient hospitalization. For hospital systems and payers, an off-the-shelf biologic that can be administered in an outpatient infusion suite represents a transformative reduction in healthcare resource utilization compared to autologous CAR-T.
2. Rational Psychoplastogen Design: Delix Therapeutics Secures $100M Series C Co-Led by J&J Innovation & DDF for DLX-001
The psychiatric treatment landscape is burdened by a profound therapeutic impasse. Classical monoaminergic reuptake inhibitors (SSRIs and SNRIs) suffer from delayed onset (taking 4 to 8 weeks to achieve therapeutic efficacy), high rates of treatment resistance (affecting over 30% of Major Depressive Disorder patients), and substantial metabolic and sexual side effects. While rapid-acting psychedelics (such as psilocybin and 5-MeO-DMT) and dissociative anesthetics (such as esketamine / Spravato) stimulate rapid cortical synaptogenesis, their clinical adoption is throttled by their powerful hallucinogenic and dissociative effects:
- Commercial delivery of Spravato requires a strict FDA Risk Evaluation and Mitigation Strategy (REMS) protocol mandating at least two hours of supervised in-clinic post-administration monitoring by healthcare professionals.
- Psychedelic-assisted psychotherapy protocols demand two therapists per patient across multi-hour dosing sessions, generating treatment costs that exceed $10,000 to $15,000 per episode of care.
On November 9, 2026, Delix Therapeutics announced the completion of an oversubscribed $100 million Series C financing round designed to commercialize a chemical solution to this bottleneck.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ RATIONAL PHARMACOLOGY: DISSOCIATING PLASTICITY FROM HALLUCINOGENESIS │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ │
│ 5-MeO-DMT / Psilocin (Hallucinogenic) Delix Zalsupindole (DLX-001 / Non-Hallucinogenic)│
│ │ │ │
│ ▼ ▼ │
│ 5-HT2A Receptor Binding 5-HT2A Receptor Binding │
│ │ │ │
│ ┌───────┴───────┐ ┌───────┴───────┐ │
│ ▼ ▼ ▼ ▼ │
│ Gq/11 Pathway β-Arrestin2 / TrkB Gq/11 Pathway β-Arrestin2 / TrkB │
│ (Phospholipase C) (mTORC1 Cascade) (Phospholipase C) (mTORC1 Cascade)│
│ │ │ │ │ │
│ ▼ ▼ ▼ ▼ │
│ IP3 & Ca2+ Wave Cortical Dendritic BLUNTED / ABSENT ROBUST CORTICAL │
│ Profound Sensory Spine Regrowth & (Zero Hallucinogenic SYNAPTOGENESIS│
│ Hallucinations Synaptogenesis Phenotype) & SPINE REGROWTH │
│ [2-Hour In-Clinic [Therapeutic Efficacy] [Take-Home Oral [Rapid Efficacy] │
│ REMS Mandate] Prescription] │
│ │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
Investor Syndicate & Governance Inflection
The Series C financing was co-led by Johnson & Johnson Innovation – JJDC, Inc. (the corporate venture arm of Johnson & Johnson) and SV Health Investors’ Dementia Discovery Fund (DDF). The round drew participation from a syndicate of leading healthcare specialists, including RA Capital Management, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures, and Bail Capital, alongside new institutional investors Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital, and YK Bioventures.
In conjunction with the raise, Christine Brennan, Ph.D. (Managing Director at JJDC) and Christian Jung, Ph.D. (Partner at SV Health Investors) joined Delix’s Board of Directors. The presence of JJDC as a co-lead is of immense strategic significance: Johnson & Johnson markets Spravato (esketamine), giving the pharmaceutical giant direct operational insight into the massive real-world logistical constraints of in-clinic psychiatric monitoring.
Biophysical Mechanism: Decoupling Synaptogenesis from Hallucinations
Delix was founded on chemical and neurobiological discoveries from the laboratory of Dr. David E. Olson at the University of California, Davis, who coined the term psychoplastogens (or neuroplastogens) to describe small molecules capable of rapidly promoting structural and functional neural plasticity.
- Chemical Scaffolding & Computational Optimization:
- Delix’s lead clinical candidate, zalsupindole (DLX-001), is a rationally designed, orally bioavailable small molecule structurally inspired by the fast-acting psychedelic 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine / mebufotenin).
- Utilizing molecular dynamics simulations and structure-activity relationship (SAR) modeling around the human serotonin $5\text{-HT}_{2\text{A}}$ receptor, Delix’s computational chemists modified the indole ring and flexible ethylamine side chain.
- These conformational modifications alter the ligand’s binding pose within the orthosteric pocket of $5\text{-HT}{2\text{A}}$, selectively blunting the intracellular $\text{G}{q/11}$-phospholipase C (PLC) signaling cascade responsible for the head-twitch response in rodents and hallucinogenic trips in humans.
- Preservation of Neuroplastic Transduction:
- Despite eliminating hallucinogenic signaling, zalsupindole retains full agonist potency at activating the $\beta\text{-arrestin2}$-mediated pathway, stimulating local brain-derived neurotrophic factor (BDNF) release, activating TrkB receptors, and driving downstream mechanistic target of rapamycin complex 1 (mTORC1) phosphorylation.
- In preclinical models of chronic stress and depression, a single oral dose of DLX-001 drives rapid (within 24 hours) regrowth of dendritic spines, increases synaptic density in the prefrontal cortex, and restores lost synaptic transmission with an effect size comparable to psilocybin and ketamine.
- Phase 1b Proof and Upcoming Phase 2b Trial:
- In Phase 1 human trials, DLX-001 demonstrated favorable oral pharmacokinetics, high blood-brain barrier penetration, and absolute tolerability with no dissociative, perceptual, or hallucinatory adverse effects.
- The $100 million Series C will fully fund a randomized, double-blind, placebo-controlled Phase 2b proof-of-concept clinical trial evaluating zalsupindole in patients with recurrent Major Depressive Disorder (MDD), scheduled to initiate in early 2027.
- The funds will also accelerate Delix’s broader preclinical and early clinical pipeline, including programs in substance use disorders, schizophrenia, and neurodegenerative conditions (such as Alzheimer’s disease and frontotemporal dementia) supported by the Dementia Discovery Fund.
Commercial Disruption: The At-Home Paradigm
The commercial thesis for neuroplastogens is simple: they convert a complex medical procedure into a standard prescription medicine. If zalsupindole replicates its Phase 1b antidepressant signals in Phase 2b without inducing perceptual disturbances, it will bypass REMS requirements, eliminate in-clinic monitoring costs, and permit standard once-daily or intermittent at-home oral administration. This positions Delix to address the $15+ billion global antidepressant market without the delivery constraints that have capped commercial adoption for first-generation psychedelic biotechs.
3. Oral Incretins Advance into Respiratory Pathology: Eli Lilly’s Foundayo (Orforglipron) Scores Phase 3 Sleep Apnea Hit at AHA 2026 Ahead of FDA Filing
Over the past two years, the metabolic therapy race between Eli Lilly and Novo Nordisk has been defined by two parameters: injection-to-oral modality transitions and the clinical expansion of incretins into non-glycemic organ pathologies. While injectable tirzepatide (Zepbound / Mounjaro) achieved FDA approval for obstructive sleep apnea (OSA) in obese adults earlier this year following the SURMOUNT-OSA trials, questions lingered over whether an oral, non-peptide small-molecule GLP-1 receptor agonist could generate sufficient systemic exposure and metabolic potency to alter structural airway collapse during sleep.
On November 9, 2026, at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago—with simultaneous publication in the Journal of the American Medical Association (JAMA)—Eli Lilly and Company (NYSE: LLY) presented decisive Phase 3 results from its ATTAIN-OSA clinical trial program (NCT06649045) evaluating its oral GLP-1 agonist Foundayo (orforglipron / LY3502970).
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ PHASE 3 ATTAIN-OSA (NCT06649045): ORAL FOUNDAYO (ORFORGLIPRON) │
├─────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Trial Population: 712 Adults with Moderate-to-Severe OSA + Obesity (BMI ≥27 kg/m²) │
│ Dosing Regimen: Once-Daily Oral Non-Peptide Capsule (52 Weeks) vs. Placebo │
├────────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Study Cohort 1: Non-PAP Patients │ Study Cohort 2: PAP-Maintained Patients │
│ (Unable or Unwilling to Use CPAP) │ (Continuing Positive Airway Pressure Therapy) │
├────────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ • Primary Endpoint: Change in AHI │ • Primary Endpoint: Change in AHI │
│ - Foundayo: -21.1 events/hr (-43.8%) │ - Foundayo: Significant Additive Reduction │
│ - Placebo: -4.3 events/hr (-8.2%) │ - Demonstrates efficacy on top of mechanical CPAP │
│ - Statistically Significant (p<0.001)│ │
│ • Disease Remission / Mild Status: │ • Hypoxic Burden Reduction: │
│ - 31.5% of Foundayo vs 10.2% Placebo │ - 45.8% drop in area-under-oxygen desaturation curve │
│ • Severe Hypoxic Burden Reduction: │ • Metabolic Health Markers: │
│ - 55.9% reduction in desaturation │ - Body Weight Loss: ~11.0% to 11.5% at Week 52 │
│ • Blood Pressure Drop: │ - Systolic BP: -7.0 to -8.0 mmHg │
└────────────────────────────────────────┴────────────────────────────────────────────────────────┘
Trial Design & Biophysical Endpoints
ATTAIN-OSA was conducted as a global, randomized, double-blind, placebo-controlled master protocol (Study GZ01 and GZ02) enrolling 712 patients across the United States, Europe, and Asia:
- Baseline Disease Burden: Patients had moderate-to-severe OSA, defined by an Apnea-Hypopnea Index (AHI) $\ge 15$ events per hour, accompanied by a body mass index (BMI) $\ge 27\text{ kg/m}^2$. Mean baseline AHI was approximately 48 events/hour (representing severe sleep apnea where breathing stops or becomes shallow almost once every minute).
- Primary Endpoint: Change in AHI from baseline to Week 52.
- Secondary Key Endpoints: Percent reduction in sleep apnea-specific hypoxic burden (a critical metric quantifying the depth and total duration of oxygen desaturation below baseline per hour of sleep, directly predictive of cardiovascular mortality), percentage of patients achieving $\ge 50%$ AHI reduction, and body weight loss.
Late-Breaking Clinical Data Points
The unblinded 52-week data demonstrated that oral orforglipron achieved clinical outcomes comparable to injectable peptide biologics:
- Dramatic Relief of Airway Obstruction:
- In patients unable or unwilling to use CPAP machines (Study GZ01), Foundayo reduced breathing events by an average of 21.1 events per hour (a 43.8% relative reduction), compared to a reduction of just 4.3 events per hour in the placebo group ($p < 0.001$).
- Nearly half (47.2%) of non-PAP patients receiving Foundayo cut their nightly apnea events by 50% or more.
- Crucially, 31.5% of patients on Foundayo achieved full disease remission or transitioned to mild OSA status (AHI $< 10$ events/hour), compared to only 10.2% on placebo.
- Reversal of Cardiovascular Hypoxic Stress:
- Foundayo reduced the sleep apnea-specific hypoxic burden by 55.9% in the non-PAP cohort and by 45.8% in patients maintaining CPAP use. Because nocturnal hypoxemia drives sympathetic overdrive, systemic hypertension, and atrial fibrillation, blunting hypoxic burden provides immediate cardiovascular protection.
- Weight Loss and Systemic Hemodynamics:
- Patients on Foundayo achieved a mean body weight reduction of 11.5% at Week 52 (compared to ~1.5% for placebo).
- Systolic blood pressure dropped by an average of 7.6 mmHg, confirming that the elimination of nocturnal apneas relieves systemic vascular resistance.
- Tolerability and Adherence:
- The safety profile of orforglipron was consistent with the GLP-1 class, dominated by transient, mild-to-moderate gastrointestinal adverse events (nausea, constipation, diarrhea) during dose escalation, with low overall discontinuation rates ($< 7%$).
Strategic Context & Regulatory Trajectory
The presentation at AHA was accompanied by a formal corporate disclosure: Eli Lilly will submit Foundayo for an FDA supplemental New Drug Application (sNDA) for moderate-to-severe obstructive sleep apnea by the end of 2026.
This filing closely follows Lilly’s September 2026 regulatory submissions for orforglipron in Type 2 diabetes. By securing late-stage data across both glycemic and respiratory-cardiovascular indications ahead of commercial launch, Lilly is constructing an expansive label for its small molecule. As an oral capsule requiring no cold-chain storage and manufactured via standard chemical synthesis rather than complex peptide solid-phase synthesis, Foundayo provides Lilly with an industrial-scale weapon to capture patients who refuse weekly injections or cannot tolerate positive airway pressure masks.
4. Unlocking the Dark Proteome and Interactome: bioRxiv Debuts $\pi$-SPECFormer (291M Spectra) and RPI-Zero (Zero-Shot RNA-Protein Interactor)
While the structural biology community has largely focused on single-protein 3D coordinate prediction (AlphaFold 3, Boltz-2, Chai-1), empirical mass spectrometry and ribonucleic acid (RNA) interactomics have remained stubborn computational bottlenecks. In classical proteomics, more than 30% to 50% of acquired tandem mass spectrometry ($\text{MS/MS}$) spectra remain unassigned (“the dark proteome”) due to non-canonical peptide sequences, unannotated somatic mutations, and complex post-translational modifications (PTMs). Concurrently, while human cells contain over 2,000 RNA-binding proteins (RBPs), fewer than 10% have been profiled experimentally by CLIP-seq, leaving the vast majority of RNA-protein interactions inaccessible to predictive modeling.
During the first week of November 2026, two milestone preprints published on bioRxiv introduced foundational deep learning architectures designed to overcome both bottlenecks.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ FRONTIER FOUNDATION MODELS IN PROTEOMICS AND INTERACTOMICS │
├────────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ π-SPECFormer (Mass Spec AI) │ RPI-Zero (Zero-Shot RNA-Protein AI) │
│ bioRxiv: 10.64898/2026.11.06.764812 │ bioRxiv: 10.64898/2026.11.04.764286 │
├────────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ • Pre-training Scale: 291M Spectra │ • Dataset: 2.1M Examples from 11.6M CLIP Peaks │
│ • Architecture: 2-Stage Self-Supervised│ • Benchmark: Strict Sequence-Clustered Splits │
│ + PSM-Guided Representation Learning │ (Evaluating Unseen RNAs & Unseen Proteins) │
│ • Capabilities: │ • Architecture: │
│ - State-of-the-art de novo sequencing│ - Joint tokenization of full proteins & RNAs │
│ - Spectrum clustering & PTM detection│ - 16 shared biological motif prototypes │
│ • Clinical Validation: │ • Capabilities: │
│ - Tested on 103 Lung Adenocarcinoma │ - Generalizes zero-shot to unprofiled RBPs │
│ patient tissue cohorts │ - Dynamically conditions RNA embeddings on target │
│ - Identified 9 somatic neoantigens │ • Open Source: Code & weights released on GitHub │
│ (6 absent from reference databases)│ │
└────────────────────────────────────────┴────────────────────────────────────────────────────────┘
1. $\pi$-SPECFormer: Pretraining on 291 Million Spectra Decodes the Dark Proteome
On November 6, 2026 (formally indexed November 9), Tianze Ling, Tao Liu, Cheng Chang, and an academic consortium published “$\pi$-SPECFormer: A Mass Spectrometry-based Foundation Model for Decoding the Dark Proteome” (bioRxiv: 10.64898/2026.11.06.764812):
- Pretraining Scale: The authors constructed the largest mass spectrometry training corpus to date, compiling 291 million raw $\text{MS/MS}$ spectra across diverse instruments (Orbitrap, TOF) and fragmentation modes (CID, HCD, ETD).
- Two-Stage Training Framework:
- Stage 1 (Self-Supervised Masked Ion Modeling): The model learns high-dimensional latent representations of peak mass-to-charge ($m/z$) ratios, intensities, and neutral losses without relying on predefined peptide sequence annotations.
- Stage 2 (PSM-Guided Contrastive Alignment): High-confidence peptide-spectrum matches (PSMs) are incorporated to align the learned spectral latent space directly with amino acid chemical geometries and fragmentation physics.
- Decoding Tumor Neoantigens in Lung Adenocarcinoma:
- The authors transferred $\pi$-SPECFormer to analyze clinical proteomic profiles from a cohort of 103 patients with lung adenocarcinoma (LUAD).
- Operating in a fully de novo sequencing regime, $\pi$-SPECFormer successfully identified nine high-confidence somatic mutated peptides.
- Crucially, six of these nine mutated peptides were completely absent from standard human reference proteome databases (UniProt and Ensembl) and could not be detected by standard database-search algorithms (such as MaxQuant or MSFragger).
- This capability provides individualized neoantigen discovery pipelines (such as those deployed by Moderna and Merck) with a direct, experimental method to validate predicted tumor neoepitopes directly from raw patient biopsy mass spectrometry.
2. RPI-Zero: Sequence-Only Zero-Shot Prediction of the RNA Interactome
On November 5, 2026, Kerim Eren, E. Irem Esendemir, and A. Ercument Cicek introduced “RPI-Zero: Zero-shot RNA-Protein Interaction Prediction” (bioRxiv: 10.64898/2026.11.04.764286):
- The Data Leakage Problem in Interactomics: Prior machine learning models for RNA-protein interaction (RPI) suffered from severe data leakage, evaluating test sets that shared high sequence homology with training data, which created an illusion of high predictive accuracy while failing completely on newly discovered proteins.
- The 2.1-Million Strict Benchmark:
- The Cicek Lab harmonized 11.6 million CLIP-seq peaks targeting 209 RNA-binding proteins across four public databases (CLIPdb, ENCODE eCLIP, POSTAR2, and POSTAR3).
- To enforce absolute zero-shot evaluation, they partitioned 2.1 million examples using strict sequence-similarity clustering into three non-overlapping evaluation slices: unseen RNAs, unseen proteins, and unseen pairs.
- Negative controls were strictly matched to positive binding events by transcript abundance and length to eliminate predictive shortcuts.
- Motif Prototype Architecture:
- RPI-Zero takes the raw primary amino acid sequence of any full-length protein and the nucleotide sequence of an RNA molecule (up to 4,096 tokens jointly) as input.
- Rather than memorizing specific protein IDs, RPI-Zero models all RNA-binding proteins as continuous mixtures over 16 shared structural motif prototypes.
- The RNA representation is conditioned dynamically on the specific protein prototype mixture, allowing the network to infer binding affinity zero-shot for unprofiled natural proteins or computationally engineered RNA-targeting effectors.
- Evaluated on the strict unseen-protein benchmark, RPI-Zero achieved substantial performance gains over existing deep learning baselines, establishing a unified foundation model for mapping RNA regulatory biology.
5. Global Bio-Capital & Licensing Discipline: Windward Bio Sets $204M Nasdaq IPO with $50M Sanofi Commitment, and Edesa Inks $140M Kyorin Pact
The financing and deal-making climate across global biopharma in the second week of November 2026 continues to reflect disciplined capital allocation. Rather than funding broad, exploratory platform discoveries, institutional capital and Big Pharma balance sheets are focusing on clinical-stage biologics, multi-target regional de-risking, and anchored syndicate structures.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ TRANSATLANTIC BIOPHARMA CAPITAL FORMATION & LICENSING │
├────────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Windward Bio Group AG (WWB) │ Edesa Biotech (EDSA) / KYORIN │
│ Nasdaq Initial Public Offering │ Exclusive Japan Licensing Pact │
├────────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ • Structure: Swiss AG Foreign Issuer │ • Asset: Paridiprubart (EB05) │
│ • Sizing: 10,294,117 Shares │ • Target: Toll-Like Receptor 4 (TLR4) mAb │
│ • Price Range: $16.00 to $18.00/share │ • Indication: Acute Respiratory Distress Syndrome │
│ • Base Gross Proceeds: ~$175.0 Million │ • Total Deal Value: >$140.0 Million │
│ • Fully Diluted Market Cap: ~$1.0B │ • Upfront Cash: $12.0 Million │
│ • Strategic Lead: SANOFI ($50M Private │ • Development/Sales Milestones: Up to $134.0M │
│ Placement Concurrent Commitment) │ • Royalties: Tiered, Double-Digit on Japan Net Sales │
│ • Syndicate: Jefferies, TD Cowen, │ • Responsibilities: Kyorin funds all Japan clinical │
│ Piper Sandler, UBS Investment Bank │ & regulatory work; Edesa retains all global rights │
└────────────────────────────────────────┴────────────────────────────────────────────────────────┘
Windward Bio: $204M IPO Backed by Sanofi Private Placement
On November 9, 2026, Switzerland-based Windward Bio Group AG filed an amended registration statement with the SEC (Form F-1/A; CIK 0002145089) setting terms for an initial public offering on the Nasdaq Global Market under the ticker symbol “WWB”:
- Offering Terms & Valuation:
- Windward plans to offer 10,294,117 common shares at an indicative price range of $16.00 to $18.00 per share.
- At the $17.00 midpoint, the base public offering will raise $175.0 million (expanding to $201.2 million if underwriters exercise their 30-day overallotment option).
- The pricing implies a fully diluted market valuation of approximately $1.02 billion.
- The Sanofi Anchor:
- Demonstrating strong corporate validation, pharmaceutical giant Sanofi executed a definitive concurrent agreement to purchase $50.0 million worth of common shares and pre-funded warrants in a separate private placement at the IPO price.
- This commitment brings total potential gross proceeds across the offering and private placement to $225.0 million to $251.2 million.
- Asset Pipeline & Clinical Focus:
- Founded by Novo Holdings and OrbiMed, Windward is deploying the proceeds to advance its clinical pipeline of ultra-long-acting monoclonal and bispecific antibodies targeting inflammatory, respiratory, and dermatologic disorders (severe asthma and chronic obstructive pulmonary disease [COPD]).
- The lead programs represent validated biologics licensed from Chinese biotech originators, reflecting the continuing Western pharma trend of acquiring cost-efficient, advanced clinical assets from China for global pivotal development.
Edesa Biotech & KYORIN Pharmaceutical: $140M ARDS Deal
Simultaneously, Canadian-American biopharmaceutical developer Edesa Biotech, Inc. (NASDAQ: EDSA; SEC CIK: 0001540159) executed a definitive collaboration and exclusive license agreement with Japan’s KYORIN Pharmaceutical Co., Ltd.:
- Transaction Economics:
- Total deal consideration exceeds $140 million, comprising an immediate $12.0 million upfront cash payment and up to $134.0 million in potential clinical development, regulatory approval, and commercial sales milestone payments.
- Edesa is entitled to receive tiered, double-digit royalties on annual net sales of the licensed product in Japan.
- Clinical Program: Paridiprubart (EB05):
- Paridiprubart is a first-in-class monoclonal antibody directed against Toll-Like Receptor 4 (TLR4), designed to block the acute inflammatory cascade that leads to pulmonary capillary leak, severe hypoxemia, and acute respiratory distress syndrome (ARDS) in patients with viral and bacterial pneumonia.
- Under the agreement, Kyorin receives exclusive commercialization and development rights for Japan and will fully fund all domestic clinical trials and regulatory interactions with Japan’s PMDA. Edesa retains all commercial rights throughout North America, Europe, and the rest of the world, and will supply clinical and commercial drug product.
- Expansion Options:
- Kyorin secured an exclusive right of first negotiation for acute kidney injury (AKI) and non-exclusive negotiation rights across secondary inflammatory indications, providing a non-dilutive funding bridge for Edesa’s ongoing Phase 3 trial operations in the West.
6. The Cardiovascular Late-Breaker Reality Check at AHA 2026: Novartis Pelacarsen Fails Phase 3 MACE, Novo Ziltivekimab Misses, while Survodutide Asserts CV Safety
The late-breaking clinical sessions at the American Heart Association (AHA) Scientific Sessions 2026 delivered a profound scientific reckoning for cardiovascular drug development. For over a decade, human genetic epidemiological studies and Mendelian randomization analyses strongly indicated that circulating Lipoprotein(a) [Lp(a)] and systemic interleukin-6 (IL-6) inflammation were independent, causal drivers of myocardial infarction, stroke, and cardiovascular death. Relying on this biomarker hypothesis, top-tier pharma invested billions of dollars developing targeted biologics to lower these circulating molecules.
Between November 6 and 9, 2026, unblinded Phase 3 late-breaking trial results published simultaneously in the New England Journal of Medicine (NEJM) dismantled several of these long-standing mechanistic assumptions.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ AHA 2026 LATE-BREAKING CARDIOVASCULAR OUTCOMES TRIALS │
├────────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Novartis Pelacarsen (Lp(a)HORIZON) │ Novo Nordisk Ziltivekimab (ZEUS) │
│ Antisense Oligonucleotide (NEJM) │ Anti-IL-6 Ligand Monoclonal Antibody │
├────────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ • Study Population: 8,324 Patients │ • Study Population: 5,100+ High-Risk CKD + ASCVD │
│ • Biomarker Hit: -78% in Serum Lp(a) │ • Biomarker Hit: Robust drop in hsCRP & IL-6 levels │
│ • Primary Endpoint (MACE): FAILED │ • Primary Endpoint (MACE): FAILED │
│ No statistically significant drop in │ No significant reduction in cardiovascular death, │
│ time-to-first CV death, MI, or stroke│ nonfatal MI, or nonfatal stroke vs. placebo │
│ • Class Impact: Threatens Amgen's │ • Tactical Pivot: Novo shifting asset toward narrow, │
│ Olpasiran (OCEAN(a)) and Lilly's │ early-stage CKD cohorts rather than broad ASCVD │
│ Lepodisiran clinical assumptions │ │
├────────────────────────────────────────┴────────────────────────────────────────────────────────┤
│ Boehringer Ingelheim & Zealand Pharma: Survodutide (SYNCHRONIZE-CVOT; NCT06077864) │
│ • Modality: Dual Glucagon / GLP-1 Receptor Agonist │
│ • Outcome: POSITIVE TOPLINE SAFETY WIN — Met Primary Endpoint with Zero Excess 5P-MACE Risk │
└─────────────────────────────────────────────────────────────────────────────────────────────────┘
1. Pelacarsen’s Phase 3 HORIZON Failure: The Lp(a) Paradox
In a packed plenary session at AHA, investigators unblinded full data from the global Phase 3 Lp(a)HORIZON trial (NCT04023552; simultaneously published in NEJM), evaluating pelacarsen (an antisense oligonucleotide co-developed by Novartis and Ionis Pharmaceuticals) in 8,324 patients with established atherosclerotic cardiovascular disease and elevated baseline Lp(a) ($\ge 70\text{ mg/dL}$):
- The Paradoxical Finding: Pelacarsen delivered a profound, sustained 78% mean reduction in circulating serum Lp(a) levels. However, over a median follow-up of 4.2 years, this dramatic biomarker clearance failed to translate into a statistically significant reduction in major adverse cardiovascular events (MACE) compared to placebo.
- Rethinking the Biology:
- The failure suggests that while genetically lifelong low Lp(a) protects against atherothrombosis, clearing circulating Lp(a) in older patients with advanced, calcified arterial plaque cannot reverse established vascular disease.
- The readout severely impacts competing RNA interference (RNAi) programs, notably Amgen’s olpasiran (currently enrolling the pivotal 6,000-patient OCEAN(a)-Outcomes trial; NCT05581303) and Eli Lilly’s lepodisiran. Analysts immediately cut the probability of success for all Lp(a)-lowering therapies from ~65% down to $< 25%$.
2. Ziltivekimab’s Phase 3 ZEUS Miss: Systemic Inflammation at the Edge
A parallel disappointment hit Novo Nordisk’s Phase 3 ZEUS trial (NCT05021835), testing the fully human interleukin-6 (IL-6) monoclonal antibody ziltivekimab in over 5,100 patients with chronic kidney disease (CKD stage 3–4) and established cardiovascular disease:
- Ziltivekimab achieved deep, sustained reductions in systemic inflammation, blunting high-sensitivity C-reactive protein (hsCRP) by over 60% to 70%.
- However, the drug failed to demonstrate a statistically significant reduction in the composite primary endpoint of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.
- Presenters noted that in end-stage or advanced CKD, microvascular calcification and metabolic derangements overpower targeted cytokine blockade, prompting Novo to pivot ziltivekimab toward earlier-stage inflammatory nephropathy cohorts.
3. Survodutide’s SYNCHRONIZE-CVOT: Dual Agonist Clears Critical Safety Hurdle
Providing a vital counterweight to the cardiovascular trial misses, Boehringer Ingelheim and partner Zealand Pharma announced that their investigational dual glucagon/GLP-1 receptor agonist survodutide (BI 456906) met its primary safety endpoint in the dedicated cardiovascular outcomes trial SYNCHRONIZE-CVOT (NCT06077864):
- Because glucagon receptor activation can theoretically induce resting tachycardia and elevate myocardial oxygen demand, establishing definitive cardiovascular safety was an essential registrational mandate.
- Survodutide successfully met its non-inferiority safety margin, demonstrating no increased risk of 5-point major adverse cardiovascular events (5P-MACE) in overweight or obese patients with high cardiovascular risk.
- This successful clearance paves the way for global regulatory filings across metabolic dysfunction-associated steatohepatitis (MASH) and obesity throughout 2027.
7. Notable Shorter Moves & Clinical Round-Up
Beyond the lead headlines, the past week featured notable corporate spin-outs, Chinese biotech platform financings, and late-stage immunology data:
Johnson & Johnson’s Oral IL-23 Peptide Hits in Phase 3 Psoriatic Arthritis
At ACR Convergence 2026, Johnson & Johnson unblinded positive Phase 3 results from the ICONIC-PsA 1 trial evaluating icotrokinra (JNJ-2113), a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor. In adult patients with active psoriatic arthritis, once-daily oral icotrokinra achieved an ACR20 response rate of 58.2% at Week 16 compared to 40.8% for placebo ($p < 0.001$), while demonstrating profound clearance of psoriasis skin plaques (PASI 75/90/100). The readout confirms that macrocyclic oral peptides can achieve the target engagement and clinical efficacy of injectable IL-23 monoclonal antibodies (such as Tremfya).
Sanyou Biopharmaceuticals Completes RMB 100M Series C
Shanghai-based Sanyou Biopharmaceuticals closed an exclusive Series C financing of approximately RMB 100 million funded by Zero2IPO Industry Investment. Sanyou will deploy the proceeds to upgrade its automated high-throughput wet-lab robotic pipelines and enhance its proprietary computational dry-lab platforms, including the AI-Super-Trillion Antibody Library (AI-STAL) and the Sanyou AI-Drug Accelerator (SAI-DA), which integrate structural generative models with automated screening to accelerate antibody discovery partnerships.
Quanome Technologies Integrates QAI Labs’ NOVA-3 Platform
In quantum-computational drug discovery, Quanome Technologies executed a definitive agreement for an all-stock strategic integration of QAI Labs. The transaction integrates QAI’s proprietary NOVA-3 platform, which combines machine learning antibody candidate selection with classical-simulated quantum optimization algorithms to evaluate multi-parameter developability, solubility, and epitope-binding landscapes.
Spruce Biosciences Spins Out Preclinical Endocrinology into Adrenyx Bio
Spruce Biosciences (NASDAQ: SPRB) announced a corporate restructuring, spinning out its early-stage preclinical endocrinology and congenital adrenal hyperplasia research assets—including its THP-1300 portfolio—into an independent, newly capitalized entity named Adrenyx Bio. The transaction allows Spruce to conserve cash and focus resources exclusively on its late-stage clinical programs.
8. Public Markets Radar, Restructurings & Capital Discipline
Trading during the week ended November 9, 2026, provided a striking case study in market structure divergence. On Monday, November 9, the broader biotech tape staged an aggressive risk-on advance:
- Across 567 actively trading biopharma equities, 441 finished higher against 114 lower (a breadth ratio of 3.9-to-1), with the cohort posting a median gain of +3.19%.
- However, as synthesized by the OpenBio News Market Desk, the session reflected a clean structural bifurcation: mechanics lifted the winners, while regulatory filings punished the losers.
┌─────────────────────────────────────────────────────────────────────────────────────────────────┐
│ THE NOVEMBER 9 TAPE: MECHANICS VS. REGULATORY FILINGS │
├────────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Thin-Float Beta Winners │ Document-Driven Decliners │
│ (Carried by Low Turnover) │ (Repriced on Real Dilution/Filings) │
├────────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ • Tvardi Therapeutics (TVRD): +47.2% │ • Onconetix (ONCO): -48.5% │
│ Volume: $6.2M on zero company filings│ Amended merger proxy cut exchange ratio for holders │
│ • Cadrenal Therapeutics (CVKD): +39.8% │ • Abeona Therapeutics (ABEO): -39.1% │
│ Volume: $516K; purely mechanical float│ Bought APT-1011 from Ellodi for $20M stock + $30M │
│ • Modular Medical (MODD): +39.1% │ placement priced at $3.75 (10% discount) │
│ Volume: $510K; non-financial survey │ • Skye Bioscience (SKYE): -30.3% (to $0.69) │
│ • Takeaway: Smallest dollar turnover │ Preliminary proxy distribution ahead of Redx merger │
│ produced the largest headline gains │ • Takeaway: Legible dilution & deal terms sold off hard│
└────────────────────────────────────────┴────────────────────────────────────────────────────────┘
The Losers’ Column: Dilution and Merger Repricings
- Abeona Therapeutics (NASDAQ: ABEO; -39.09% to $3.80; SEC CIK: 0000318306):
- Dropped nearly 40% after releasing two concurrent SEC Form 8-K filings on Monday morning.
- First, Abeona acquired APT-1011 (an oral disintegrating fluticasone for eosinophilic esophagitis) from Ellodi Pharmaceuticals for 4.49 million shares of common stock ($20 million value) plus $60 million in contingent milestones.
- Second, to fund clinical operations, Abeona sold 6.4 million shares and 1.6 million pre-funded warrants in a $30 million registered direct placement at $3.75 per share—a steep discount to Friday’s close. Compounded by Q3 ZEVASKYN commercial revenue of $13.5 million missing consensus expectations, the dilution wiped $90 million off ABEO’s market capitalization.
- Onconetix (NASDAQ: ONCO; -48.49%):
- The session’s worst performer plunged after filing an amended merger agreement that significantly revised the stock exchange ratio against legacy shareholders in its pending business combination.
- Skye Bioscience (NASDAQ: SKYE; -30.32% to $0.69; SEC CIK: 0001516551):
- Broke below the critical $1.00 compliance mark, continuing a multi-session sell-off following its preliminary proxy filing for its combination with Redx Pharma to form Fibrx Therapeutics paired with a $125 million financing.
Corporate Restructurings: Crinetics WARN Notices
Following Vertex Pharmaceuticals’ (NASDAQ: VRTX) landmark $10 billion acquisition of Crinetics Pharmaceuticals, formal WARN notices were filed in California disclosing post-merger operational consolidations and commercial team realignments, continuing the industry-wide mandate to trim duplicate discovery overhead while preserving clinical execution budgets.
9. Deduplication Audit & Provenance Matrix
In strict accordance with OpenBio News editorial standards, all companies, clinical programs, foundation models, and transactions in this review were audited against our coverage database across the preceding 30 days:
| Organization | Asset / Program | Clinical ID / Verified Link | Previous Coverage Status | Verified Developments in Current Window (Nov 3–9, 2026) | Editorial Disposition |
|---|---|---|---|---|---|
| Nkarta, Inc. | NKX019 (Allogeneic CAR-NK) | NCT06557265 / NCT05020678 | Never previously covered | Unblinded Phase 1/2 autoimmune data at ACR 2026: 83–86% response rates, zero CRS/ICANS | Lead Headline 1 (Part A) |
| CRISPR Therapeutics | Zugo-cel (CTX112) | NCT05643742 | Never previously covered | Presented Plenary ACR data: 83% rCRISS-25 in SSc, 100% TIS in myositis, zero ICANS | Lead Headline 1 (Part B) |
| Delix Therapeutics | Zalsupindole (DLX-001) | Company Disclosures | Mentioned in 2023 review; Series C never covered | Closed $100M Series C co-led by JJDC & DDF for Phase 2b MDD trial | Lead Headline 2 |
| Eli Lilly and Company | Foundayo (Orforglipron) | NCT06649045 | T2D submissions noted in Sept; sleep apnea never covered | Phase 3 ATTAIN-OSA presented at AHA & published in JAMA; planned sNDA by end-2026 | Lead Headline 3 |
| bioRxiv / Ling et al. | $\pi$-SPECFormer | bioRxiv: 10.64898/2026.11.06.764812 | Never previously covered | Published 291M-spectrum foundation model identifying dark proteome neoantigens | Lead Headline 4 (Part A) |
| bioRxiv / Eren et al. | RPI-Zero | bioRxiv: 10.64898/2026.11.04.764286 | Never previously covered | Published zero-shot sequence-only RNA-protein interaction model on 2.1M pairs | Lead Headline 4 (Part B) |
| Windward Bio Group AG | Clinical Respiratory Pipeline | SEC Form F-1/A CIK 0002145089 | Initial F-1 noted in Oct; IPO terms never covered | Set terms for up to $204M Nasdaq IPO with $50M concurrent Sanofi private placement | Lead Headline 5 (Part A) |
| Edesa Biotech / Kyorin | Paridiprubart (EB05) | SEC Form 8-K CIK 0001540159 | Never previously covered | Executed $140M exclusive Japan licensing agreement for ARDS | Lead Headline 5 (Part B) |
| Novartis / Ionis | Pelacarsen (Lp(a)HORIZON) | NCT04023552 | Preliminary headline noted in daily news; full data never analyzed | Full Phase 3 HORIZON NEJM data presented at AHA: 78% Lp(a) drop failed MACE | Lead Headline 6 (Part A) |
| Novo Nordisk | Ziltivekimab (ZEUS) | NCT05021835 | Never previously covered | Phase 3 ZEUS unblinded at AHA: missed composite cardiovascular primary endpoint | Lead Headline 6 (Part B) |
| Boehringer / Zealand | Survodutide (SYNCHRONIZE-CVOT) | NCT06077864 | Never previously covered | Met primary endpoint in SYNCHRONIZE-CVOT, clearing cardiovascular safety profile | Lead Headline 6 (Part C) |
| Johnson & Johnson | Icotrokinra (ICONIC-PsA 1) | SEC Form 10-Q CIK 0000200406 | Psoriasis noted in prior review; PsA Phase 3 never covered | Unblinded Phase 3 ICONIC-PsA 1 at ACR: 58% ACR20 vs 41% placebo | Notable Move 1 |
| Abeona Therapeutics | APT-1011 & Placement | SEC Form 8-K CIK 0000318306 | Covered in daily movers; never in weekly review | Stock down 39% on $20M asset acquisition + $30M placement at $3.75 | Public Markets Radar |
10. Upcoming Clinical & Regulatory Catalysts (Late 2026 – Mid 2027)
| Estimated Timing | Company / Sponsor | Asset / Modality | Indication / Study | Expected Catalyst / Milestone |
|---|---|---|---|---|
| Late 2026 | Eli Lilly and Company | Foundayo (Orforglipron) | Moderate-to-Severe OSA | Submission of supplemental New Drug Application (sNDA) to US FDA |
| Late 2026 | Windward Bio Group AG | WWB Pipeline | Respiratory & Immunology | Completion of Nasdaq IPO (WWB) and closing of $50M Sanofi placement |
| Q1 2027 | Nkarta, Inc. | NKX019 (CAR-NK) | Myositis & Systemic Sclerosis | FDA Type B meeting to finalize registrational trial designs in rheumatology |
| Q1 2027 | Delix Therapeutics | Zalsupindole (DLX-001) | Major Depressive Disorder | Initiation of randomized, double-blind Phase 2b proof-of-concept trial |
| H1 2027 | CRISPR Therapeutics | Zugo-cel (CTX112) | Systemic Lupus & Sclerosis | Expanded Phase 1/2 cohort data and pivotal trial design disclosures |
| H1 2027 | Boehringer Ingelheim | Survodutide (Dual Agonist) | MASH & Obesity | Global regulatory filings across US and Europe following CVOT clearance |
| Mid 2027 | Amgen | Olpasiran (RNAi) | OCEAN(a)-Outcomes (ASCVD) | Potential interim assessment or trial redesign following pelacarsen miss |
11. Primary Sources & Verified Citations
Clinical Trials & Regulatory Registries
- U.S. National Library of Medicine Clinical Trials Registry:
- Nkarta NTRUST-1 Autoimmune Basket Trial: NCT06557265
- Nkarta Phase 1 Multicenter Oncology & Basket Program: NCT05020678
- CRISPR Therapeutics CTX112 (Zugo-cel) Allogeneic CAR-T Trial: NCT05643742
- Eli Lilly and Company Master Protocol for Orforglipron in OSA (ATTAIN-OSA): NCT06649045
- Novartis Pelacarsen Phase 3 Cardiovascular Outcomes Study (Lp(a)HORIZON): NCT04023552
- Novo Nordisk Ziltivekimab Cardiovascular Outcomes Trial (ZEUS): NCT05021835
- Boehringer Ingelheim Survodutide Cardiovascular Safety Trial (SYNCHRONIZE-CVOT): NCT06077864
- Amgen Olpasiran Cardiovascular Outcomes Trial (OCEAN(a)-Outcomes): NCT05581303
Scientific Preprints & Peer-Reviewed Literature
- bioRxiv Preprint Server:
- Tianze Ling, Tao Liu, Cheng Chang et al., $\pi$-SPECFormer: A Mass Spectrometry-based Foundation Model for Decoding the Dark Proteome, bioRxiv: 10.64898/2026.11.06.764812
- Kerim Eren, E. Irem Esendemir, A. Ercument Cicek et al., RPI-Zero: Zero-shot RNA-Protein Interaction Prediction, bioRxiv: 10.64898/2026.11.04.764286
- Selena Setsu, Kotaro Tsuboyama et al., Massively parallel quantification and prediction of monomeric protein yield in Escherichia coli, bioRxiv: 10.64898/2026.11.02.763507
Regulatory Filings (U.S. Securities & Exchange Commission)
- Windward Bio Group AG: SEC EDGAR Form F-1/A Registration Statement (CIK 0002145089)
- Edesa Biotech, Inc.: SEC EDGAR Form 8-K License Disclosure (CIK 0001540159)
- Nkarta, Inc.: SEC EDGAR Corporate Disclosures (CIK 0001787400)
- CRISPR Therapeutics AG: SEC EDGAR Periodic Reports (CIK 0001674416)
- Eli Lilly and Company: SEC EDGAR Form 10-Q & 8-K Reports (CIK 0000059478)
- Abeona Therapeutics Inc.: SEC EDGAR Form 8-K Asset Purchase & Registered Direct Placement (CIK 0000318306)
- Skye Bioscience, Inc.: SEC EDGAR Form 8-K & Merger Proxy Disclosures (CIK 0001516551)
- Johnson & Johnson: SEC EDGAR Form 10-Q Filings (CIK 0000200406)
Institutional & Corporate Disclosures
- Delix Therapeutics Corporate Announcements: Delix Therapeutics Official Portal